LNTH vs. QDEL, NEOG, RIOT, CLDX, NTLA, MYGN, DOCS, CRSP, HAE, and PRGO
Should you be buying Lantheus stock or one of its competitors? The main competitors of Lantheus include QuidelOrtho (QDEL), Neogen (NEOG), Riot Platforms (RIOT), Celldex Therapeutics (CLDX), Intellia Therapeutics (NTLA), Myriad Genetics (MYGN), Doximity (DOCS), CRISPR Therapeutics (CRSP), Haemonetics (HAE), and Perrigo (PRGO).
QuidelOrtho (NASDAQ:QDEL) and Lantheus (NASDAQ:LNTH) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.
QuidelOrtho received 111 more outperform votes than Lantheus when rated by MarketBeat users. Likewise, 67.23% of users gave QuidelOrtho an outperform vote while only 65.21% of users gave Lantheus an outperform vote.
In the previous week, Lantheus had 3 more articles in the media than QuidelOrtho. MarketBeat recorded 23 mentions for Lantheus and 20 mentions for QuidelOrtho. QuidelOrtho's average media sentiment score of 0.48 beat Lantheus' score of 0.12 indicating that Lantheus is being referred to more favorably in the news media.
QuidelOrtho has a beta of 0.17, meaning that its stock price is 83% less volatile than the S&P 500. Comparatively, Lantheus has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500.
Lantheus has lower revenue, but higher earnings than QuidelOrtho. QuidelOrtho is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.
QuidelOrtho presently has a consensus target price of $61.60, suggesting a potential upside of 44.94%. Lantheus has a consensus target price of $99.17, suggesting a potential upside of 31.29%. Given Lantheus' higher possible upside, equities research analysts clearly believe QuidelOrtho is more favorable than Lantheus.
Lantheus has a net margin of 33.72% compared to Lantheus' net margin of -0.34%. QuidelOrtho's return on equity of 54.10% beat Lantheus' return on equity.
99.0% of QuidelOrtho shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 1.0% of QuidelOrtho shares are held by company insiders. Comparatively, 1.5% of Lantheus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Lantheus beats QuidelOrtho on 14 of the 18 factors compared between the two stocks.
Get Lantheus News Delivered to You Automatically
Sign up to receive the latest news and ratings for LNTH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lantheus Competitors List
Related Companies and Tools
